AOD-9604 is a lab-made piece of human growth hormone, built to test whether the fat-burning part of the hormone could work on its own. It is a short peptide made of 16 amino acids. An early human trial showed a small weight difference, but a larger and longer trial found no significant weight loss, and its development as an obesity drug ended in 2007.
The sections below explain what AOD-9604 is, how it was meant to work, and what the studies found.
Key takeaways
- AOD-9604 is a modified fragment of growth hormone, not the whole hormone.
- It was designed for fat loss without the other effects of growth hormone.
- A 24-week trial in 536 people did not show significant weight loss versus placebo.
- The only joint data come from rabbits. No human joint trials exist.
What Is AOD-9604?
AOD-9604 is a synthetic peptide. A peptide is a short chain of amino acids, the building blocks of protein. This one has 16 of them.
The name stands for “Advanced Obesity Drug.” Researchers at Monash University in Australia built on work showing that the tail end of human growth hormone seemed to drive fat breakdown. A company called Metabolic Pharmaceuticals then developed the compound. It takes that tail piece and adds one extra amino acid at the start to make it more stable.
People also search for it as the “AOD-9604 peptide.” Both names refer to the same compound.
How Is AOD-9604 Different From Growth Hormone?
A fragment is one small piece cut from a larger protein. Human growth hormone has 191 amino acids. AOD-9604 uses only the last short section, plus one extra.
The idea was simple. Growth hormone does many things in the body. It affects growth, muscle, fat and blood sugar. Researchers wondered if the piece tied to fat could be separated from the rest.
| Feature | Growth hormone | AOD-9604 |
|---|---|---|
| Size | 191 amino acids | 16 amino acids |
| What it is | The full hormone | A modified tail fragment |
| Design goal | Many effects in the body | Fat breakdown only |
| IGF-1 effect | Raises IGF-1, a growth signal made in the liver | Designed not to raise it |
This is also different from peptides that tell the body to make more of its own hormone. Those are covered in the peptides that release growth hormone comparison. Tesamorelin works in that way, and it has human trial data on belly fat, as covered in tesamorelin research and side effects. AOD-9604 does not release growth hormone at all. It is only a fragment.
How Does AOD-9604 Work?
The proposed idea is called lipolysis. That means breaking stored fat into smaller parts that cells can burn for energy. In animal studies, the fragment was reported to affect how fat cells handle fat.
A simple comparison: growth hormone is a full toolbox. AOD-9604 was meant to be a single tool taken from it, the one used for fat.
This is a working idea based on animal work. It did not hold up well in the largest human trial.
What Does the Research Say?
| Study | Study type | Key finding |
|---|---|---|
| Early studies in rodents | Animal studies | Reported effects on fat metabolism in obese animals. |
| Early phase 2 obesity trial (about 300 adults, 12 weeks) | Human trial | A small weight difference against placebo was reported. |
| OPTIONS trial (536 adults, 24 weeks) | Human phase 2b trial | No significant weight loss against placebo. |
| Kwon et al., 2015 | Rabbit study | Injections into the knee were linked to better cartilage repair. |
Trial summaries also report that across roughly six human trials, side effects looked similar to placebo, and that IGF-1 levels did not change.
Researchers who work with compounds like this usually source them from trusted platforms such as PeptidePro and ask for a certificate of analysis, or COA. A COA is a lab report that shows what is in the vial and how pure it is.
Why Did AOD-9604 Fail as a Weight-Loss Drug?
The story comes down to two trials.
- The early trial was smaller and shorter. It reported about 2.6 kg of weight loss on the best-performing dose, against about 0.8 kg on placebo.
- The later trial was larger and longer. It enrolled 536 people for 24 weeks and found no significant difference against placebo.
In the early trial, higher doses also did not work better than lower ones. That is unusual, because a real drug effect normally grows with the dose.
The company ended its obesity program in 2007. When a small early result is not repeated in a larger trial, researchers usually trust the larger one.
Does AOD-9604 Help Joints or Cartilage?
There is a small amount of animal data. In a 2015 rabbit study, injections into a knee with induced arthritis were linked to better cartilage repair, alone or with hyaluronic acid, a joint lubricant.
That is the whole joint story so far. No human trial has shown that AOD-9604 helps joints. Rabbit results often do not carry over to people.
How Does AOD-9604 Compare With Newer Weight-Loss Peptides?
The weight-loss landscape has moved on. Drugs that act on gut hormones produced much larger results in big human trials, with average losses in the double digits as a percent of body weight. The difference between them is explained in tirzepatide compared with semaglutide.
AOD-9604 works in a different way and has not matched those results. For a wider look at the topic, see the discussion of peptides and weight loss safety.
AOD-9604 Side Effects and Safety in Studies
Trial summaries describe side effects that were similar to placebo. That sounds reassuring, but the limits matter:
- The trials were short, with the longest at 24 weeks.
- Most participants were adults with obesity, not other groups.
- Safety of products sold as research chemicals depends on quality, which varies.
- Long-term safety has not been studied.
A lack of reported problems in short trials does not prove long-term safety.
Is AOD-9604 Banned in Sport?
Yes, AOD-9604 is named on the World Anti-Doping Agency’s Prohibited List under growth hormone fragments. Athletes should check the current list for the latest wording.
FAQs
What is AOD-9604?
AOD-9604 is a synthetic peptide of 16 amino acids, modified from the tail end of human growth hormone. It was designed to promote fat breakdown. A small early trial showed a slight weight difference, but a larger trial did not show significant weight loss.
Does AOD-9604 work?
Not as a weight-loss drug, based on its largest trial. A 24-week study of 536 people found no significant weight loss against placebo. An earlier small trial had shown a modest difference, but it was not repeated. Evidence for other uses is limited to animals.
Is AOD-9604 growth hormone?
No. AOD-9604 is a small fragment of growth hormone with one amino acid added. It does not contain the whole hormone and was designed not to raise IGF-1. It is also different from peptides that make the body release its own growth hormone.
Has AOD-9604 been tested in humans?
Yes. Metabolic Pharmaceuticals ran about six human trials with roughly 900 people, according to trial summaries. The main obesity trial had 536 participants and did not meet its goal. No human trials have shown benefit for joints or cartilage.
Is AOD-9604 a steroid?
No. A steroid is a type of fat-based hormone molecule. AOD-9604 is a peptide made of amino acids. It is a fragment of growth hormone, which is also a protein hormone, not a steroid.
This content is for educational and research purposes only. The compounds discussed are not intended for human consumption. Nothing here is medical advice. For any peptide use, readers should consult an expert who can advise what works best for them.